Business
ValiSeek Development Update - Recruitment Closes
ValiSeek Development Update - Recruitment Closes.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 1252I ValiRx PLC 15 June 2017 \n\n \n \n \nValiRx Plc\n(\"ValiRx\" or \"the Company\")\n \nValiSeek Clinical Development Update\nRecruitment closes\n \nLondon, UK., 15 June 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to provide an update on the clinical development of ValiSeek Limited (\"ValiSeek\"), the joint venture (\"JV\") between ValiRx and Tangent Reprofiling Limited.\n \nValiSeek was formed to progress the novel cancer treatment drug, VAL401, into clinical trials for the treatment of lung cancer and other oncology indications. Since its last clinical update on 8 March 2017, ValiSeek is pleased to report continued progress of the trial of VAL401 in the treatment of non-small cell lung cancer.\n \nThe VAL401 trial treating patients with non-small cell lung cancer has completed the recruitment phase. ValiSeek has decided there was no requirement to enrol further patients and will continue to measure the outcomes of those patients currently on trial, while commencing analysis of the results to date.\n \nA total of 8 patients have been enrolled into the trial for treatment and the data collected from these participants, will be compared to data being collected in case-matched untreated patients from the same clinics, providing a minimum of a 20 subject cohort for data comparison. \n \nAs announced previously, the protocol allows a preliminary datalock after collection of all \"Day 15\" pharmacokinetic samples. Now that recruitment is complete, the data checking and database formation for these figures is underway, after which they will be passed to the analysis team. This process of data processing and analysis is expected to be returned in Q3.\n \nThe protocol allows dosing of patients for up to six months, so the trial remains on track to be completed by the year end, following which further data processing and analysis will be performed.\n \nThese details will be discussed by Dr Suzanne Dilly, CEO of ValiSeek at the BIO International Convention in San Diego next week (June 19 - 22). (For more information on the BIO International Convention, please see below) \n \nDr Suzy Dilly, CEO of ValiSeek, commented: \"We are delighted to have been able to close on schedule, due to ...